account_balance
Investment manager · 13F filer · SEC CIK 1055951
Orbimed Advisors LLC
Reported value$5.28Bas of Jun 30, 2026
Positions121 35 new, 21 sold out
Top 10 weight43%EWTX alone is 12%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
EWTX
Edgewise Therapeutics Inc
11.9%
ELVN
Enliven Therapeutics Inc
6.5%Trimmed
LLY
Eli Lilly & Co
5.9%Added
MBX
MBX Biosciences Inc
3.6%Trimmed
Sinovac Biotech Ltd
Sinovac Biotech Ltd
3.5%
AZN
Astrazeneca PLC
3.2%Added
GPCR
Structure Therapeutics Inc
2.2%Added
SION
Sionna Therapeutics Inc
2.1%Trimmed
CRVS
Corvus Pharmaceuticals Inc
2.0%
AVBP
Arrivent Biopharma Inc
2.0%
111 others
57.0%
Box size is the share of the fund's reported holdings. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
What changed